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Introduction
Interferon-α (IFNα) is an antiviral, immunomodulatory and antiproliferative cytokine which is produced in response to a variety of infectious agents including viruses and bacteria. 1 It constitutes a key component of natural immunity linking innate and adaptive immune responses. IFNα activates macrophages, induces dendritic cell maturation, enhances CD4+ T helper-1 and NK cell-mediated immunity, supports B cell differentiation to antibody-secreting plasma cells and promotes the generation of effector T cells. 2 In line with these activities, IFNα has been utilized in the treatment of chronic viral infections and diverse neoplastic conditions including hematological malignancies and solid tumors. [3] [4] [5] Furthermore, IFNα has been shown to function as a potent adjuvant in a variety of animal models acting as a the third signal in the induction of CD8+ T cell immune response 6 and is currently being used in a number of vaccination trials. 7 On the other side, IFNα treatment may cause immune-mediated tissue damage and induces the development of autoimmune diseases. 8, 9 Moreover, IFNα alters hematopoiesis and during high-dose IFNα therapy, 26-60 % of patients develop neutropenia, anemia and thrombocytopenia requiring discontinuation of the therapy. 10 Several mechanisms responsible for hematologic toxicity have been identified. It has been shown that IFNα impairs the replication and differentiation of megakaryocytic and erythrocytic progenitor cells resulting in thrombocytopenia and anemia. [11] [12] [13] [14] It also blocks granulopoietic differentiation leading to accumulation of granulocyte-macrophage colony forming cells (GM-CFC). 15 In addition, IFNα causes lymphopenia, an effect which has been ascribed to redistribution of lymphocytes from the peripheral circulation to lymphoid organs. 16 Furthermore IFNα acts on hematopoietic stem cells (HSCs) altering their dormancy.
HSCs constitute a minute cell population of pluripotent cells capable of generating all blood cell lineages for a life-time. Under steady-state conditions, HSCs are mainly in dormancy to avoid exhaustion. Upon hematopoietic stress, HSCs rapidly and transiently expand and differentiate to replenish blood cells. It has been shown that Lymphocytic
Choriomeningitis Virus (LCMV)-induced transient bone marrow (BM) aplasia was due to IFN type I produced shortly after viral infection. 17 The same authors demonstrated that LCMV infection caused depletion of pluripotent and lineage committed hematopoietic progenitors in WT but no in IFNα/β receptor deficient animals. Thus, type I IFN can act directly on quiescent long-term hematopoietic stem cells (LT-HSC) forcing them to enter the cell cycle. In fact, it is suggested that interferon may play a role in the mechanism of the acute erythroblastopenic crisis occasionally observed in patients with chronic anemia following viral infections. 18 More recently it has been shown that IFNα induces proliferation of HSCs and that maintained exposure to this cytokine by repeated poly(I:C) administration leads to HSC exhaustion. 19, 20 However, these results have recently been questioned by studies showing that upon poly(I:C) administration, the HSC pool proliferates transiently to enter subsequently into quiescence being thus protected from the killing effects of IFNs. 21 Therefore the consequences on HSC function of chronic exposure to IFNα still need to be characterized.
In the present work, we have investigated the consequences of long term IFNα treatment on blood cell homeostasis using an adenoassociated viral vector (AAV) expressing murine IFNα under the control of a constitutive promoter. We showed that sustained IFNα exposure depletes the LT-HSC and short term HSCs (ST-HSC) reservoir and, at the same time, drives BM lymphopoiesis towards generation of T cell precursors at the expense of other lymphocyte subsets. This effect is associated with the transcriptional modulation of a number of factors involved in blood cell lineage specification.
Methods

Mice and treatment
Experiments were performed with 6-8 weeks-old male C57BL/6 mice purchased from
Harlan Laboratories (Barcelona, Spain). RAG-1-deficient (RAG1-/-) mice were bred and maintained under pathogen-free conditions in the animal facility of the University of Navarra. The experimental design was approved by the Ethical Committee for Animal
Testing of the University of Navarra. Mice were injected intravenously with AAV vectors. For all procedures, animals were anesthetized by intraperitoneal injection of a mixture of xylacine (Rompun 2%, Bayer) and ketamin (Imalgene 500, Merial) 1:9 v/v.
Viral construction, production and purification
The expression cassette contained in the AAV-IFNα plasmid consist of the murine interferon-alpha-2 gene (GenBank accession number NM_010503) under the transcriptional control of the constitutive and ubiquitous promoter of human elongation factor-1 (GenBank accession number J04617.1). As control IFNα gene was replaced by luciferase to obtain the AAV-luc. rAAV8 vectors were produced as previously described. 22 Viral titers in terms of viral genome per milliliter (vg/ml) were determined by Q-PCR.
Flow cytometry and cell sorting
All flow cytometry and cell sorting (FACS) studies were performed on single-cell suspensions and cells were stained using standard protocols. In a second study mice were treated as previously described and blood cell count analysis was performed at different days. We observed a fast and dramatic decrease of leukocytes in all the animals receiving IFNα probably due to the redistribution from the peripheral circulation to marginal and tissue pools. 16 Thereafter, leukocyte count very slowly 
Sustained IFNα expression diminished HSCs compartment
Homeostasis of blood cells is dependent on dormant BM HSCs possessing long-term self-renewal capacity. Thus, we analyzed the effect of sustained IFNα production on BM HSCs. One month after vector injection, mice were sacrificed and the total number of BM cells was determined. As shown in Figure Using Lin-c-kit+ (LK) as identification markers for HSC, our analysis revealed a dose-dependent decrease of LK population in mice treated with AAV-IFNα ( Figure 3B ).
0
The analysis of the LK cells with anti-CD48 and anti-CD150, which discriminates between LT-HSCs (LK, CD48-, CD150+), ST-HSCs (LK, CD48-, CD150-), and multipotent progenitors (MPPs: LK, CD48+, CD150-), revealed a profound and dose-dependent decrease of all three populations in animals treated with IFNα ( Figure   3C -F). In particular, LT-HSCs nearly disappeared after high dose treatment ( Figure 3D ).
We further investigated the influence of IFNα on the more differentiated progenitor cells.
We analysed by flow cytometry the percentage of common lymphoid progenitors (CLPs:
Lin-cKit lo CD127+ Thy1.2-), using the gating strategy described in Supplementary 
Long term IFNα treatment guides multipotent hematopoietic progenitor cells toward a T cell fate
To analyze the functionality of MPPs obtained from IFNα treated mice we carried out the experiment represented in Figure 5A . C57BL/6 CD45.1+ mice received 5x10 12 
Discussion
IFNα exerts potent antiviral, antitumor and adjuvant effects but these activities are counterbalanced by the induction of peripheral pancytopenia which frequently limits its clinical use. 10 It has also been shown that viral infections repress hematopoiesis in an IFNα-dependent manner. 17 Moreover, recently it has been reported that repeated administrations of interferon inducers, like poly(I:C), alter HSCs quiescence provoking HSCs exhaustion. 19, 20 Thus, IFNα exerts a complex impact on hematopoiesis, it compromises the stemness of HSCs but also redirects the function of the hematopoietic precursors. In this sense IFNα is known to induce lymphopenia but at the same time, it is a vigorous stimulator of T cell immunity. 6, 16 Although a large amount of information exits about the beneficial and deleterious effects of IFNα the modulation of hematopoiesis by IFNα still remains poorly understood.
Here we analyzed the hematopoietic changes occurring in mice subjected to chronic IFNα This finding is consistent with the reduction in erythrocytes and platelets occurring during IFNα therapy and shows that, besides the reported effect of IFNα on replication and differentiation of megakaryocytic and erythrocytic progenitor cells.
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Several hematopoietic cytokines regulate hematopoiesis by controlling the proliferation, differentiation, and maturation of primitive hematopoietic cells. Student's t-test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). 
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